Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-400 in advanced solid tumors
NCT05029882Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2021
- Primary completion
- Nov 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 10
01
Overview
Phase 1, open-label trial of telisotuzumab adizutecan in non-small cell lung cancer (NSCLC), gastroesophageal adenocarcinoma, colorectal cancer (CRC) and 1 more (12 arms), sponsored by AbbVie Inc. Primary endpoint: Objective Response Rate at 48 months. Started Oct 2021; status: active, not recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
non-small cell lung cancer (NSCLC)gastroesophageal adenocarcinomacolorectal cancer (CRC)solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05029882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05029882.